A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
European Journal of Cancer2013Vol. 49(18), pp. 3763–3772
Citations Over TimeTop 10% of 2013 papers
Miguel Martín, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, István Láng, Sung‐Bae Kim, Caroline Germa, Jennifer Vermette, Kenneth Wang, Kongming Wang, Ahmad Awada
Related Papers
- → Pyrotinib versus lapatinib in HER2-positive breast cancer(2019)14 cited
- → Lapatinib: A competitor or companion to trastuzumab?(2009)8 cited
- → Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation(2013)4 cited
- → Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient(2013)5 cited
- → Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.(2013)3 cited